Syros Pharmaceuticals Analyst Ratings
Syros Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 137.3% | Piper Sandler | $11 → $7 | Maintains | Overweight |
| 08/09/2023 | 408.51% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/11/2023 | 408.51% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/11/2023 | 408.51% | JMP Securities | $16 → $15 | Maintains | Market Outperform |
| 03/03/2023 | 340.71% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 03/03/2023 | 408.51% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 01/05/2023 | 578.01% | Piper Sandler | $27 → $20 | Maintains | Overweight |
| 11/15/2022 | 442.41% | JMP Securities | $40 → $16 | Maintains | Market Outperform |
| 11/15/2022 | 408.51% | Oppenheimer | $30 → $15 | Maintains | Outperform |
| 11/15/2022 | 578.01% | HC Wainwright & Co. | $6 → $20 | Maintains | Buy |
| 08/10/2022 | 1.7% | Oppenheimer | $9 → $3 | Maintains | Outperform |
| 07/12/2022 | 103.4% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 05/17/2022 | 239.01% | HC Wainwright & Co. | $15 → $10 | Maintains | Buy |
| 05/17/2022 | 239.01% | Alliance Global Partners | $14 → $10 | Maintains | Buy |
| 09/23/2021 | 679.71% | Roth Capital | $20 → $23 | Maintains | Buy |
| 11/04/2020 | 408.51% | HC Wainwright & Co. | $11 → $15 | Upgrades | Neutral → Buy |
| 03/06/2020 | 171.2% | HC Wainwright & Co. | $10 → $8 | Reiterates | → Neutral |
| 01/17/2020 | 205.11% | Wedbush | → $9 | Downgrades | Outperform → Neutral |
| 10/18/2019 | 442.41% | JMP Securities | $18 → $16 | Maintains | Market Outperform |
| 02/14/2019 | — | Oppenheimer | Assumes | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/03/2023 | 137.3% | 派珀·桑德勒 | $11→$7 | 维护 | 超重 |
| 08/09/2023 | 408.51% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 2023年05月11日 | 408.51% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 2023年05月11日 | 408.51% | JMP证券 | $16→$15 | 维护 | 市场表现强于大盘 |
| 03/03/2023 | 340.71% | 奥本海默 | $15→$13 | 维护 | 跑赢大盘 |
| 03/03/2023 | 408.51% | HC Wainwright公司 | →$15 | 重申 | →购买 |
| 01/05/2023 | 578.01% | 派珀·桑德勒 | $27→$20 | 维护 | 超重 |
| 2022年11月15日 | 442.41% | JMP证券 | $40→$16 | 维护 | 市场表现强于大盘 |
| 2022年11月15日 | 408.51% | 奥本海默 | $30→$15 | 维护 | 跑赢大盘 |
| 2022年11月15日 | 578.01% | HC Wainwright公司 | $6→$20 | 维护 | 买 |
| 2022年08月10日 | 1.7% | 奥本海默 | $9→$3 | 维护 | 跑赢大盘 |
| 07/12/2022 | 103.4% | HC Wainwright公司 | $10→$6 | 维护 | 买 |
| 2022/05/17 | 239.01% | HC Wainwright公司 | $15→$10 | 维护 | 买 |
| 2022/05/17 | 239.01% | 联盟全球合作伙伴 | $14→$10 | 维护 | 买 |
| 09/23/2021 | 679.71% | 罗斯资本 | $20→$23 | 维护 | 买 |
| 11/04/2020 | 408.51% | HC Wainwright公司 | $11→$15 | 升级 | 中性→购买 |
| 03/06/2020 | 171.2% | HC Wainwright公司 | $10→$8 | 重申 | →中性 |
| 2020/01/17 | 205.11% | 韦德布什 | →$9 | 评级下调 | 跑赢→中性 |
| 2019年10月18日 | 442.41% | JMP证券 | $18→$16 | 维护 | 市场表现强于大盘 |
| 2019年02月14日 | - | 奥本海默 | 假设 | →跑赢大盘 |
What is the target price for Syros Pharmaceuticals (SYRS)?
Syros PharmPharmticals(SYRS)的目标价是多少？
The latest price target for Syros Pharmaceuticals (NASDAQ: SYRS) was reported by Piper Sandler on October 3, 2023. The analyst firm set a price target for $7.00 expecting SYRS to rise to within 12 months (a possible 137.30% upside). 10 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年10月3日报道了赛洛斯制药(纳斯达克：SYRS)的最新目标价。这家分析公司将目标价定为7美元，预计SYR将在12个月内升至(可能上涨137.30%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Syros Pharmaceuticals (SYRS)?
分析师对Syros PharmPharmticals(SYRS)的最新评级是多少？
The latest analyst rating for Syros Pharmaceuticals (NASDAQ: SYRS) was provided by Piper Sandler, and Syros Pharmaceuticals maintained their overweight rating.
纳斯达克(Sequoia Capital：SYRS)的最新分析师评级由Piper Sandler提供，Syros PharmPharmticals维持增持评级。
When is the next analyst rating going to be posted or updated for Syros Pharmaceuticals (SYRS)?
Syros PharmPharmticals(SYRS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Syros制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Syros制药的上一次评级是在2023年10月3日提交的，所以你应该预计下一次评级将在2024年10月3日左右的某个时候公布。
Is the Analyst Rating Syros Pharmaceuticals (SYRS) correct?
分析师对Syros PharmPharmticals(SYRS)的评级正确吗？
While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a maintained with a price target of $11.00 to $7.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $2.95, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但Syros PharmPharmticals(SYRS)的最新评级保持不变，目标价在11.00美元至7.00美元之间。Syros PharmPharmticals(SYRS)目前的交易价格为2.95美元，超出了分析师的预测区间。